Camp4 Therapeutics Corporation (CAMP)

Market Cap	96.97M
Revenue (ttm)	n/a
Net Income (ttm)	-51.50M
Shares Out	20.16M
EPS (ttm)	-106.23
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,312
Open	4.900
Previous Close	4.830
Day's Range	4.663 - 4.900
52-Week Range	3.500 - 12.300
Beta	n/a
Analysts	Buy
Price Target	19.33 (+301.87%)
Earnings Date	Nov 21, 2024

About CAMP

Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops regulatory RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-CPS-001 for the treatment of urea cycle disorders. The company also develops CMP-SYNGAP to treat synaptic Ras GTPase activating protein 1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 11, 2024
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: CAMP
• Website: https://www.camp4tx.com

Financial Performance

Financial numbers in USD

Analyst Forecast

According to 4 analysts, the average rating for CAMP stock is "Buy." The 12-month stock price forecast is $19.33, which is an increase of 301.87% from the latest price.

Price Target

$19.33

(301.87% upside)

Analyst Consensus: Buy